Follow us on Twitter
twitter icon@FreshPatents


Immune Response patents

      

This page is updated frequently with new Immune Response-related patent applications.




 Treatment of inflammatory and dysimmune response patent thumbnailTreatment of inflammatory and dysimmune response
A drug and, more particularly, to a drug for treating inflammatory and dysimmune response. The present invention also relates to a drug for treating graft-versus-host disease.
Chu De Dijon


 Disease therapy by inducing immune response to trop-2 expressing cells patent thumbnailDisease therapy by inducing immune response to trop-2 expressing cells
The present invention concerns compositions and methods of use of bispecific antibodies comprising at least one binding site for trop-2 (egp-1) and at least one binding site for cd3. The bispecific antibodies are of use for inducing an immune response against a trop-2 expressing tumor, such as carcinoma of the esophagus, pancreas, lung, stomach, colon, rectum, urinary bladder, breast, ovary, uterus, kidney or prostate.
Ibc Pharmaceuticals, Inc.


 Method for in vivo expansion of t regulatory cells patent thumbnailMethod for in vivo expansion of t regulatory cells
Compositions specific for tnf-receptor superfamily member 25 (tnfrsf25, dr3) modulate the immune response by regulating t regulatory cells.. .
University Of Miami


 Antibody therapeutics that bind cd137 patent thumbnailAntibody therapeutics that bind cd137
There is disclosed compositions and methods relating to or derived from anti-cd137 antibodies. More specifically, there is disclosed fully human antibodies that bind cd137, cd137-antibody binding fragments and derivatives of such antibodies, and cd137-binding polypeptides comprising such fragments.
Sorrento Therapeutics, Inc.


 An anti-cd45rc antibody for use as drug patent thumbnailAn anti-cd45rc antibody for use as drug
The invention relates to an isolated anti-cd45rc antibody for use in preventing or treating transplant rejection, autoimmune diseases, unwanted immune responses against proteins expressed in the course of gene therapy and/or therapeutic proteins, allergy as well as lymphoma or cancer which are associated with cd45rc+ cells. The invention relates to an isolated anti-cd45rc antibody for use in expanding and/or potentiating regulatory t cells..
UniversitÉ De Nantes


 Methods of modulating an immune response patent thumbnailMethods of modulating an immune response
The present invention relates to monoclonal antibodies and antigen-binding portions thereof that specifically bind to a filovirus (e.g., marburg virus (marv)), including antibodies that cross-react with at least two filoviruses. Such antibodies are useful for the prevention and treatment of filovirus infection.

 Adenocarcinoma antigenic determinants and methods patent thumbnailAdenocarcinoma antigenic determinants and methods
Adenocarcinoma antigenic determinants, methods for their production and use, and broadly-specific human monoclonal antibodies reactive to the epitopes. These epitopes, which can be physically recapitulated, are conserved across a range of adenocarcinomas and are capable of eliciting an immune response in humans..
Vaccinogen, Inc.


 Vaccine adjuvant compositions patent thumbnailVaccine adjuvant compositions
Embodiments described herein relate to combinatorial compositions and uses thereof, for example, as vaccine adjuvant compositions, for enhancing immune response, for inducing differentiation of nave t cells to differentiate into ifn-γ-producing t cells, and for preventing and treating infections. The combinatorial composition comprises tlr and clr agonists.
Children's Medical Center Corporation


 Therapeutic compositiojns and methods for inducing an immune response to herpes simplex virus type 2 (hsv-2) patent thumbnailTherapeutic compositiojns and methods for inducing an immune response to herpes simplex virus type 2 (hsv-2)
Disclosed are therapeutic compositions and methods for inducing an immune response to herpes simplex virus type 2 (hsv-2). More particularly, the invention relates to a method for inducing an immune response in a subject by introducing and expressing an hsv gd2-encoding dna vaccine..
Admedus Vaccines Pty Ltd


 Recombinant bacterium and methods of antigen and nucleic acid delivery patent thumbnailRecombinant bacterium and methods of antigen and nucleic acid delivery
The present invention provides a recombinant bacterium and methods of using the recombinant bacterium to induce an immune response.. .
The Arizona Board Of Regents For And On Behalf Of Arizona State University


Carrier molecule for antigens

The invention provides a conjugate comprising an antigen and a carrier molecule, wherein the carrier molecule comprises a bp-2a antigen and a spb1 antigen. Bp-2a and spb1 are streptococcus agalactiae antigens.
Glaxosmithkline Biologicals Sa

Cancer therapy using a vaccine in combination with a cell-based immunotherapeutic agent

A cancer therapy composition and a method of cancer treatment by inducing humoral and cellular immune responses against cancer cells in a patient is provided. The method includes administering to the patient a therapeutically effective amount of a vaccine, wherein the vaccine includes at least one tumor-associated antigen, at least one immunostimulant, and at least one lipid capable of forming a multilamellar liposome, or non-lipid molecule capable of forming a vesicle or gel.
Xeme Biopharma Inc.

Therapeutic cancer vaccine containing tumor-associated neoantigens and immunostimulants in a delivery system

A therapeutic vaccine and a method of cancer treatment by inducing humoral and cellular immune responses against malignant cells is provided. The vaccine comprises a delivery system that incorporates at least one peptide whose sequence encompasses a genetic mutation associated with a malignancy (neoantigen), at least one immunostimulant, and at least one type of lipid molecule..
Xeme Biopharma Inc.

Cdca1 epitope peptides for th1 cells and vaccines containing the same

Isolated cdca1-derived epitope peptides having th1 cell inducibility are disclosed herein. Such peptides can be recognized by mhc class ii molecules and induce th1 cells.
Oncotherapy Science, Inc.

Materials and methods for improving immune responses and skin and/or mucosal barrier functions

The subject invention provides compositions and methods for treating human dermatological conditions by employing a microbiome-centered treatment approach. Preferred embodiments of the invention provide pharmaceutical and cosmetic compositions, and the methods of using the same, comprising a strain of lactobacillus fermentum bacterium, or bioactive extracts thereof, derived from human microbiota and capable of growing in biofilm phenotype..
Quorum Innovations, Llc

Discovery of regulatory t cells programmed to suppress an immune response

A method to treat an autoimmune disease is provided. The method involves administration of interleukin-15 receptor (il-15r) agonists in an amount effective to ameliorate a symptom of the autoimmune disease.
Dana-farber Cancer Institute, Inc.

Malaria antigen screening method

The invention provides a method of identifying an antigen from a pathogen or a disease antigen comprising the use of an adenoviral vector array comprising two or more different adenoviral vectors, wherein each adenoviral vector comprises a nucleic acid sequence encoding a different antigen of a pathogen. The adenoviral vectors are administered to antigen presenting cells (apcs) in vitro or to an animal in vivo.
United States Of America As Represented By The Secretary Of The Navy

Expression system for modulating an immune response

The present invention discloses methods and compositions for modulating the quality of an immune response to a target antigen in a mammal, which response results from the expression of a polynucleotide that encodes at least a portion of the target antigen, wherein the quality is modulated by replacing at least one codon of the polynucleotide with a synonymous codon that has a higher or lower preference of usage by the mammal to confer the immune response than the codon it replaces.. .
Admedus Vaccines Pty Ltd.

Compositions and methods related to antibodies to staphylococcal protein a

Embodiments concern methods and compositions for treating or preventing a bacterial infection, particularly infection by a staphylococcus bacterium. Aspects include methods and compositions for providing a passive immune response against the bacteria.
The University Of Chicago

Innate immune system modification for anticancer therapy

The present invention relates to the discovery of a role of the nuclear receptor retinoid-related orphan receptor gamma (rorgamma) in tumor suppression. The introduction and expression of rorgamma result in genes activation within innate immune cells that trigger recognition and suppression of tumor cells.
Yale University

Messenger rna nanoparticles and preparation method therefor

Disclosed are nanoparticles that are introduced into cells and express a specific protein and a manufacturing method thereof. More particularly, the present invention relates to mrna nanoparticles, which increase the expression of a specific protein capable of stimulating the cellular immune system to induce cellular immune responses and are thus applicable to treat a variety of diseases, do not require passage across the nuclear envelope because a desired gene is delivered not as plasmid dna itself but in the form of mrna, thus improving the efficiency of protein expression, and the nanoparticles are generated through a one-step process with a relatively small amount of plasmid dna via rolling circle transcription (rct), thereby providing a simple and economical process for gene delivery.
University Of Seoul Industry Cooperation Foundation

Vaccine pharmaceutical composition for transdermal administration

The present invention provides a vaccine pharmaceutical composition for transdermal administration which is safe, usable as a prophylactic or therapeutic agent for cancer or infectious diseases, and capable of safely and effectively inducing a systemic immune response. It can be administered to a human or animal skin, the vaccine pharmaceutical composition including: a lipopolysaccharide or its salt derived from at least one gram-negative bacterium such as serratia, lelercia, rahnella, acidicaldus, acidiphilium, acidisphaera, acidocella, acidomonas, asaia, belnapia, craurococcus, gluconacetobacter, gluconobacter, kozakia, leahibacter, muricoccus, neoasaia, oleomonas, paracraurococcus, rhodopila, roseococcus, rubritepida, saccharibacter, stella, swaminathania, teichococcus, zavarzinia, pseudomonas, achromobacter, bacillus, methanoculleus, methanosarcina, clostridium, micrococcus, flavobacterium, pantoea, acetobacter, zymomonas, xanthomonas, and enterobacter, as an immunostimulant; and at least one antigen, the vaccine pharmaceutical composition having a mass ratio between the immunostimulant and the antigen, the total mass of the immunostimulant/the total mass of the antigen, of 0.002 to 500..
Nitto Denko Corporation

Vaccine for treatment and prevention of herpes simplex virus infection

The present invention relates to methods and compositions for the prevention and treatment of herpes virus infections. The invention provides antigenic peptides, and pharmaceutical compositions comprising complexes of antigenic peptides and adjuvants that can activate an immune response against herpes viruses.
Agenus Inc.

Compositions and methods for transient immune response modulation during vaccination

In certain aspects the invention provides a selection of hiv-1 envelopes suitable for use as immunogens, and methods of using these immunogens to induce neutralizing antibodies. In certain embodiments, the immunogens are designed to trimerize.
Duke University

Bacterial vaccines deficient in the 2-c-methyl-d-erythritol-4-phosphate pathway and methods of preparation and use thereof

The present invention relates to the preparation and use in primates of whole organismvaccines in which the mep pathway is disrupted such that synthesis of hmbpp by the bacterial cells is substantially blocked. The data provided demonstrates that, when bacteria or other vaccine vectors that comprise an active mep pathway are used in vaccine methods, the γδ t cell response dominates, potentially clearing the vaccine strain via γδ t cell-mediated killing of vector infected antigen presenting cells and reducing its utility as a stimulator of a productive adaptive immune response, specifically priming or boosting of cd4+ and cd8+ αβ t cell responses, specific for listerial-encoded antigens.
Providence Health & Services-oregon D/b/a Providence Portland Medical Center

Modulated immunodominance therapy

The invention involves generating a t cell response to subdominant antigens and using the cells to therapeutically change the cellular homeostasis and nature of the immune response. In a preferred embodiment, the cells are generated outside of the patient avoiding the influence of the patient's immunologic milieu.
Geneius Biotechnology, Inc.

Inoculation by applying nanosecond pulsed electric fields to a biopsy and reintroducing the treated biopsy to the subject

A subject is inoculated from a disease by exposing a biopsy of a tumor or other abnormal growth to a nanosecond pulsed electric field (nspef). A sufficient treatment can be confirmed by detecting calreticulin on the tumor cell membranes, which indicates apoptosis occurring in the tumor cells.
Pulse Biosciences, Inc.

Methods and therapeutic combinations for treating tumors

Methods and therapeutic combinations useful for increasing cell-mediated anti-tumor responses are described. The methods include administering to a subject a therapeutically effective amount of an immune response modifier compound and a therapeutically effective amount of one or more immune checkpoint inhibitor compounds..
Board Of Regents, The University Of Texas System

Predictive value of clostridium difficile-specific immune response for recurrence and disease outcome

The present invention relates to the field of clostridium difficile infections. Methods of diagnosing, treating and preventing clostridium difficile-associated disease and recurrent cdad are disclosed herein..
Assistance Publique - Hopitaux De Paris

Use of pdl1 expressing cells to convert t cells into regulatory t cells

The present invention provides methods and compositions for converting a t cell into a cell that exhibits at least one regulatory t cell phenotype. The converted t cell is generated by contacting a t cell with a cell that is modified to comprise an agent capable of activating pd1 signaling in a t cell.
The United States Of America, As Represented By The Secretary, Department Of Health And Human

Carbon nanotube compositions and methods of use thereof

Carbon nanotube (cnt)-based compositions for activating cellular immune responses are provided. The cnts function as high surface area scaffolds for the attachment of t cell ligands and/or antigens.
Yale University

Monovalent anti-cd3 adjuvants

This document provides methods and materials related to using monovalent anti-cd3 antibodies (e.g., monovalent anti-cd3 fab fragments) as adjuvants to increase the immune response produced against an antigen (e.g., a tumor associated antigen). For example, vaccine compositions containing monovalent anti-cd3γε fab fragments in combination with tumor associated antigens (e.g., tumor associated antigens having little or no immunogenicity in the absence of monovalent anti-cd3γε fab fragments) alone or in combination with adjuvants for signals two and/or three required for full activation of t cell immune function, as well as methods and materials for using monovalent anti-cd3γε fab fragments to increase the immune response produced against an antigen (e.g., a tumor associated antigen) within a mammal (e.g., a human) are provided..
Mayo Foundation For Medical Education And Research

A combination of kynurenine and antigen presenting cells (apc) as therapeutics and methods for their use in immune modulation

This invention provides combinations of kynurenine and antigen presenting cells (apc) for modulating immune tolerance, wherein the combinations may be used to modulate an autoimmune response, which may be of use in the treatment of type 1 diabetes (t1d) or alopecia areata (aa). Uses of kynurenine and antigen presenting cells (apc) as an immune modulator for the treatment of t1d or aa are also provided..
The University Of British Columbia

Activation of innate immunity for enhanced nuclear reprogramming of somatic cells with mrna

The nuclear reprogramming of somatic cells with mrna encoding reprogramming factors is shown to be greatly accelerated by activation of innate immune responses in the somatic cell. Methods of activating innate immunity include activation of pkr, of toll-like receptors, e.g.
The Board Of Trustees Of The Leland Stanford Junior University

Antagonistic peptides

The present invention relates to a compositions and methods for treating and/or preventing neurologic disorders such as alzheimer's disease and disorders associated with an increase of the th2 immune response such as allergic inflammation.. .
Deakin University

Vaccine delivery method

The present invention includes a composition including as one component a slurry matrix that is a liquid at room temperature and a gel at physiological ph, physiological salt concentrations and/or physiological temperatures and as a second component one or more antigens. Also include are methods of inducing an immune response in a subject and vaccinating a subject by administering such compositions..
University Of Georgia Research Foundation, Inc.

Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof

The present invention relates to an immunostimulatory composition comprising a) an adjuvant component, comprising or consisting of at least one (m)rna, complexed with a cationic or polycationic compound, and b) at least one free mrna, encoding at least one therapeutically active protein, antigen, allergen and/or antibody, wherein the immunostimulatory composition is capable to elicit or enhance an innate and optionally an adaptive immune response in a mammal. The inventive immunostimulatory composition may be a pharmaceutical composition or a vaccine.
Curevac Ag

Methods and compositions for inhibiting akt3

Compounds and compositions for selectively inhibiting akt3 are provided. Methods of using the compounds are also provided.
Augusta University Research Institute, Inc.

Adjuvanted influenza vaccines for pediatric use

An influenza vaccine adjuvanted with a sub-micron oil-in-water emulsion elicits significantly higher immune responses in human pediatric populations. Compared to an existing unadjuvanted pediatric influenza vaccine, the adjuvanted vaccines provided herein can induce in children a longer persistence of high serum antibody titers and also longer seroconversion and seroprotection.
Seqirus Uk Limited

Defective ribosomal products in blebs (dribbles) and methods of use to stimulate an immune response

Methods are disclosed for producing defective ribosomal products (drips) in blebs (dribbles) by contacting cells with a proteasome inhibitor, and in some examples also an autophagy inducer, thereby producing treated cells. Dribbles can be used to load antigen presenting cells (apcs), thereby allowing the apcs to present the drips and antigenic fragments thereof.
Providence Health & Services - Oregon

Computationally optimized broadly reactive antigens for influenza

The development of a computationally optimized influenza ha protein that elicits broadly reactive immune response to all h5n1 influenza virus isolates is described. The optimized ha protein was developed through a series of ha protein alignments, and subsequent generation of consensus sequences, for clade 2 h5n1 influenza virus isolates.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education

Anti-mycoplasma spp. subunit vaccine

Provided in the present invention are anti-mycoplasma spp. Subunit vaccines, especially proteins suitable for being used as the active ingredient of the mycoplasma spp.
Agricultural Technology Research Institute

Ompa and asp14 in vaccine compositions and as diagnostic targets

Anaplasma phagocytophilum surface proteins asp14 and ompa and homologous genes from anaplasmatacaea family members are used in compositions suitable for vaccines to treat or prevent infections caused by tick-born bacteria of the anaplasmatacaea family. Asp14 and/or ompa proteins or peptide fragments may be used in combination with other anaplasmatacaea surface proteins to elicit an immune response.
Virginia Commonwealth University

Transgenic algae for delivering antigens to an animal

Delivery systems and methods are provided for delivering a biologically active protein to a host animal. The systems and methods provided include obtaining an algal cell transformed by an expression vector, the expression vector comprising a nucleotide sequence coding for the biologically active protein, operably linked to a promoter.
The Ohio State University

Novel immunotherapy against several tumors, such as lung cancer, including nsclc

The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

An isolated interleukin-34 polypeptide for use in preventing transplant rejection and treating autoimmune diseases

The invention relates to an isolated interleukin-34 (il-34) polypeptide for use in preventing or treating graft rejection, autoimmune disease, unwanted immune response against therapeutic proteins and allergy. The invention also provides an in vitro method for determining whether a patient is at risk of transplant rejection, autoimmune diseases, unwanted immune response against therapeutic proteins or allergies, comprising a step of determining the expression level of il-34 in a biological sample obtained from said patient, wherein the presence of il-34 is indicative of a reduced risk of transplant rejection, autoimmune diseases, unwanted immune response against therapeutic proteins or allergies..
UniversitÉ De Nantes

Use of annexin v as a method to block tumor induced immunosuppression of the innate immune response

Methods are provided for treating a subject with cancer, with a therapeutic dose of annexin v to the subject.. .
The Board Of Trustees Of The Leland Stanford Junior University

Pegylated recombinant bacteriophage

The present invention provides a recombinantly modified pegylated bacteriophage expressing a mammalian antigen presenting cell chemoattractant. The present invention further provides methods of treatment of mammalian subjects having a bacterial infection by the administration of a pharmaceutically acceptable formulation of a recombinantly modified pegylated bacteriophage expressing a mammalian antigen presenting cell chemoattractant.

Specific akt3 inhibitor and uses thereof cross-reference to related applications

Methods of selectively inhibiting akt3 are provided. It has been discovered that 4-[(6-nitroquinolin-4-yl)amino]-n-[4-(pyridin-4-ylamino)phenyl]benzamide selectively inhibits akt3.
Augusta University Research Institute, Inc.

Psgl-1 modulators and uses thereof

The present invention relates to the seminal discovery that p-selectin glycoprotein ligand-1 (psgl-1) modulates the immune system and immune responses. Specifically, the present invention provides psgl-1 agonists and antagonists which increase the survival of multifunctional t cells and viral clearance.
Sanford-burnham Medical Research Institute

Antibody guided vaccines and methods of use for generation of rapid mature immune responses

Adjuvant compositions, vaccines, constructs for preparing the adjuvant compositions and vaccines and methods of using the adjuvant compositions and vaccines to enhance immune responses in subjects are provided herein. In particular, a rapid antibody response to the vaccine including both igg (in the circulation) and siga (mucosal secretory iga) is elicited.
The Texas A&m University System

Adjuvant for mucosal vaccine

An object of the present invention is to provide an adjuvant for a mucosal vaccine with high safety that induces a sufficient immune response in a mucosal membrane. According to the present invention, an adjuvant for a mucosal vaccine containing a protein complex composed of hemagglutinin (ha) subcomponents ha1 and ha2, and mutant subcomponent ha3 of botulinum toxin is provided..
Osaka University

Vaccination in newborns and infants

The present invention relates to vaccines comprising at least one mrna encoding at least one antigen for use in the treatment of a disease in newborns and/or infants, preferably exhibiting an age of not more than 2 years, preferably of not more than 1 year, more preferably of not more than 9 months or even 6 months, wherein the treatment comprises vaccination of the newborn or infant and eliciting an immune response in said newborn or infant. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit..
Curevac Ag

Microneedle compositions and methods of using same

Described herein, are microneedle devices comprising a recombinant alphavirus replicon encoding an exogenous polypeptide, wherein the recombinant alphavirus replicon is coated onto or embedded into a plurality of microneedles. Also described herein are methods of preparing a microneedle device comprising a recombinant alphavirus replicon encoding an exogenous polypeptide.
Verndari, Inc.

Novel method and compositions

The present invention relates to, inter alia, a method of raising an immune response against a pathogen which comprises administering (i) one or more first immunogenic polypeptides derived from said pathogen; (ii) one or more adenoviral vectors comprising one or more heterologous polynucleotides encoding one or more second immunogenic polypeptides derived from said pathogen; and (iii) an adjuvant; wherein the one or more first immunogenic polypeptides, the one or more adenoviral vectors and the adjuvant are administered concomitantly. The invention also relates to vaccines, pharmaceutical compositions, kits and uses employing said polypeptides, adenoviral vectors and adjuvants..
Glaxosmithkline Biologicals, S.a.

Anti-mycoplasma spp. subunit vaccine

Provided in the present invention are anti-mycoplasma spp. Subunit vaccines, especially proteins suitable for being used as the active ingredient of the mycoplasma spp.
Agricultural Technology Research Institute

Kif20a epitope peptides for th1 cells and vaccines containing the same

Isolated kif20a-derived epitope peptides having th1 cell inducibility are disclosed herein. Such peptides can be recognized by mhc class ii molecules and induce th1 cells.
Oncotherapy Science, Inc.

Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector

Compositions and methods are provided herein for improved dual immunization strategies that induce in a subject a robust immune response. The methods described are therefore useful for treating and/or preventing (i.e., reducing the likelihood or risk of occurrence) different diseases, disorders, and conditions such as cancers and infectious diseases for which induction of a humoral immune response and/or cellular immune response is desired and beneficial..
Immune Design Corp.

A method to up-regulate cancer stem cell markers for the generation of antigen specific cytotoxic effector t cells

The invention concerns a method of preparing a composition comprising stimulated immune system cells such as dendritic cells (dc) for use in inducing immune response of cytotoxic t lymphocytes against colorectal cancer. The dendritic cells are pulsed by contact with colorectal cancer stem cells (csc) or their fragments thereof.
Tessa Therapeutics Pte. Ltd.

Anti-psgl-1 antibodies

Immunoglobulin chains or antibodies having light or heavy chain complementarity determining regions of antibodies that bind to p-selectin glycoprotein ligand-1. Also disclosed are methods of inducing death of an activated t-cell and of modulating a t cell-mediated immune response in a subject..
Abgenomics Cooperatief U.a.

Peptides mimicking hiv-1 viral epitopes in the v2 loop for the gp120 surface envelope glycoprotein

The present invention relates to an isolated immunogenic peptide comprising a v2 loop fragment from hiv surface envelope glycoprotein gp120. This peptide binds specifically with antibodies in blood of patients vaccinated with a vaccine that has shown protection from hiv-1 infection, does not react with blood of matched patients who did not receive the vaccine, and can, therefore, elicit anti-hiv-1 antibodies which protect against hiv-1 infection.
New York University

Immunomodulatory compositions and methods for treating disease with modified host defense peptides

Compositions and methods are provided for modulating an immune response in a vertebrate subject. Compositions and methods can comprise administering a modified host defense peptide to the vertebrate subject in an amount effective to activate the immune response in the vertebrate subject, wherein the modified host defense peptide is inverted in amino acid sequence from an amino terminus to a carboxy terminus or modified to one or more d-amino acids, or both modifications, when compared to a host defense peptide.
University Of Saskatchewan

Pharmaceutical combinations for immunotherapy

The present invention relates generally to a method for regulating immune reactions and test substances useful for same. Specifically, the method of the present invention relates to the modulation of the nerve growth factor receptor p75ntr, which is expressed by plasmacytoid dendritic cells.
Technische Universitat Dresden

Lipidated immune response modifier compound compositions, formulations, and methods

The compound n-(4-{[4-amino-2-butyl-1h-imidazo[4,5-c]quinolin-1-yl]oxy}butyl) octadecanamide is a useful drug compound for enhancing immune response and can be used, for example, as a vaccine adjuvant and a cancer treatment.. .
3m Innovative Properties Company

Peptide mixture

There is disclosed a peptide mixture suitable for eliciting an immune response. It comprises a first and a second peptide, each corresponding to a fragment of the ras protein.
Targovax Asa

Novel peptides and combination of peptides for use in immunotherapy against various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

New medical agents and uses thereof

The invention provides a novel compounds derived from cd154, but without the intracellular domain. Notably, the invention provides tmz-cd154 and a method to treat diseases in which the novel molecule tmz-cd154 is used.
Lokon Pharma Ab

Syndecan-4 proteoliposomes for enhanced cutaneous wound healing and minimized inflammatory immune response

Disclosed herein are compositions and articles for wound healing that contain proteovesicles, comprising a syndecan polypeptide embedded in a lipid vesicle, and a pdgf polypeptide. Also disclosed is the use of these compositions to enhance wound healing..
Board Of Regents, The University Of Texas System

Immune mediated cancer cell destruction, systems and methods

Systems and methods for delivering electric fields to a target tissue of a patient for destruction of cancerous cells so as to elicit or induce a specific anti-cancerous cell immune response in the patient.. .
Lazure Scientific, Inc.

Methods and materials for treating medical conditions

This document provided methods and materials involved in treating medical conditions. For example, methods and materials for using anti-interleukin 4, anti-interleukin 5, and/or anti-interleukin 13 antibodies to treat asthma in a mammal identified as having a th2 immune response using a whole blood cell-based cytokine whole blood cell-based cytokine assay are provided..
Mayo Foundation For Medical Education And Research

Methods for enhancing the efficacy of a tumor-directed immune response

As described below, the present invention features methods for enhancing the efficacy of a tumor antigen in inducing an anti-cancer immune response in a subject by administering an ox40 agonist and an indoleamine 2,3-dioxygenase (ido) inhibitor with the tumor antigen.. .
Augusta University Research Institute, Inc.

Synthetic glucopyranosyl lipid adjuvants

Or a pharmaceutically acceptable salt thereof, wherein l1, l2, l3, l4, l5, l6, l7, l8, l9, l10, y1, y2, y3, y4, r1, r2, r3, r4, r5, r6, are as defined herein. Pharmaceutical compositions, vaccine compositions, and related methods for inducing or enhancing immune responses, are also provided..

Vaccines with interleukin-17 as an adjuvant

Disclosed herein is a vaccine comprising an antigen and il-17. Also disclosed herein is a method for increasing an immune response in a subject.
Beijing Advaccine Biotechnology Co. Ltd

Vaccination with mrna-coded antigens

The present invention relates to vaccines comprising at least one mrna encoding at least one antigen for use in the treatment of a disease in an elderly patient preferably exhibiting an age of at least 50 years, more preferably of at least 55 years, 60 years, 65 years, 70 years, or older, wherein the treatment comprises vaccination of the patient and eliciting an immune response in said patient. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit..
Curevac Ag

Composite antigenic sequences and vaccines

The invention relates to composite antigens comprising a peptide with contiguous amino acid sequence derived from a plurality of antigenic epitopes of one or more pathogens that induces an immune response in a mammal that is protective against infection by the one or more pathogens. In addition, the invention relates to vaccines comprising composite antigens and to method for treating and preventing an infection..
Longhorn Vaccines And Diagnostics, Llc

Cd40 ligand fusion protein vaccine

Provided are methods of generating an immune response to any of various antigens including foreign antigens such as infectious agent antigens. In general, the method comprises administering an expression vector encoding a transcription unit encoding a secretable fusion protein, the fusion protein containing the foreign antigen and cd40 ligand and also administering the encoded fusion protein.
Microvax, Llc

Anti-mycoplasma spp. subunit vaccine

Provided in the present invention are anti-mycoplasma spp. Subunit vaccines, especially proteins suitable for being used as the active ingredient of the mycoplasma spp.
Agricultural Technology Research Institute

Anti-mycoplasma spp. subunit vaccine

Provided in the present invention are anti-mycoplasma spp. Subunit vaccines, especially proteins suitable for being used as the active ingredient of the mycoplasma spp.
Agricultural Technology Research Institute

Anti-mycoplasma spp. subunit vaccine

Provided in the present invention are anti-mycoplasma spp. Subunit vaccines, especially proteins suitable for being used as the active ingredient of the mycoplasma spp.
Agricultural Technology Research Institute

Induced activation in dendritic cells

The present invention is directed to a composition and method which to treat diseases and to enhance a regulated immune response. More particularly, the present invention is drawn to compositions that are based on dendritic cells modified to express an inducible form of a co-stimulatory polypeptide..
Baylor College Of Medicine

Breast and ovarian cancer vaccines

The compositions described herein include an epitope of a peptide that may elicit an immune response in a subject following administration. The compositions may comprise nucleic acids.
University Of Washington Through Its Center For Commercialization

Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection

Vaccine, vectors and methods of using the vaccine vectors to enhance the immune response to an apicomplexan parasite and reduce the morbidity or mortality associated with subsequent infection are provided herein. The vaccine vectors include a polynucleotide encoding a rhomboid polypeptide and optionally include an immune-stimulatory polypeptide suitably expressed on the surface of the vaccine vector..
The Texas A&m University System

Rna-based compositions and adjuvants for prophylactic and therapeutic treatment

The present invention is directed towards an artificial rna nanostructure comprising multiple external strands of rna, each external strand comprising about 40-50 nucleotides; one internal strand of rna comprising more than about 50 nucleotides; the internal strands and external strands assembled to form a triangle nanostructure, a square nanostructure, or a polygon nanostructure and a prna three-way junction (3wj) motif at each vertex of the nanostructure. Such nanostructure can be provided in a composition together with an adjuvant for use in inducing the production of high affinity neutralizing antibodies or inhibitory antibodies, inducing the production of cytokines, inducing an immune response in a subject, or a combination thereof..
University Of Kentucky Research Foundation

Self assembling nucleic acid nanostructures

Stable self-assembling nucleic acid nanostructures comprising: —a plurality of oligonucleotides, —a plurality of g-quadruplex forming nucleic acids linked to the plurality of oligonucleotides, and —a plurality of g-quadruplex stabilizing domains linked to the g-quadruplex forming nucleic acids. The nucleic acid nanostructures are suitable for use as agonists or antagonists of nucleic acid interacting complexes, such as toll-like receptors; for inhibiting dna or rna expression; for stimulating or inhibiting an immune response; and for treating diseases such as cancer, infectious diseases, allergies and allergic diseases, and autoimmune diseases..
Exicure, Inc.

Compositions and methods relating to the treatment of diseases

The present invention relates to compositions and methods for promoting the induction of a cell-mediated immune response (such as that mediated by th1 cells) and the suppression of a humoral or allergic immune response (such as that mediated by th2 and th17 cells). In particular, the invention relates to compositions and methods for preventing or treating allergy, such as food allergy, and associated allergic diseases, and conditions where an exaggerated th17 response plays a detrimental role.
Alfacyte Ltd

Pharmaceutical compositions and methods to vaccinate against candidiasis

A candida albicans bloodstream infections cause significant morbidity and mortality in hospitalized patients. Filament formation and adherence to host cells are critical virulence factors of c.
Los Angeles Biomedical Research Institute At Harbor-ucla Medical Center

Treatment of infection

The invention relates to compositions including a substance useful as an adjuvant for potentiating an immune response, and methods of using the composition in individuals with infections of tissue within or adjacent to a transformation zone, such as the transformation zone of the cervix or anal canal.. .

Vaccine

The present invention is based on the finding that microorganisms can be modified so as to express certain factors important in generating or raising host immune responses. In particular, the invention provides modified microorganisms which, when subjected to conditions which would be expected to suppress or reduce the expression, function and/or activity of certain factors, exhibit increased (often significantly increased) expression, and/or activity of those factors.
Moredun Research Institute

Immune health for companion animals

The invention provides methods for promoting and/or improving immune health in a companion animal. In one embodiment, a method for improving immune health in a companion animal, comprising administering a composition comprising non-replicating lactobacillus paracasei to the companion animal, wherein the composition is administered in an amount effective for increasing immune response in the animal..
Nestec Sa

Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against cll and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Identification of pneumocystis antigens and uses thereof

Pneumonia due to the fungus pneumocystis jirovecii is a life-threatening infection that occurs in immunocompromised patients. The inability to culture the organism as well as the lack of a sequenced genome has hindered antigen discovery that could be useful in developing effective vaccines, therapeutic antibodies and diagnostic methods.
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College

Immunotherapeutic composition, treatment, and diagnosis

Disclosed herein is a immunotherapeutic composition comprising il-17. Also disclosed herein is a method of increasing an immune response in a subject in need thereof.

Method and system for treating cancer cachexia

Various embodiments of the present invention are directed to the field of oncology, and in particular embodiments directed to a method of ameliorating, treating, or preventing a malignancy in a human subject wherein the steps of the method assist or boost the immune system in eradicating cancerous cells. In certain embodiments, administration of beneficial bacteria to an individual's microbiome that have been modified so as to produce effective amounts of desired compositions, compounds, agents, e.g.

Immune-modifying nanoparticles for the treatment of inflammatory diseases

The current invention involves the administration of negatively charged particles, such as polystyrene, plga, or diamond particles, to subjects to ameliorate inflammatory immune responses. Additionally, the present invention describes methods of treating inflammatory diseases by administering these same negatively charged particles..
Cour Pharmaceuticals Development Company, Inc.

Early cancer detection and enhanced immunotherapy

A method of therapy for a tumor or other pathology by administering a combination of thermotherapy and immunotherapy optionally combined with gene delivery. The combination therapy beneficially treats the tumor and prevents tumor recurrence, either locally or at a different site, by boosting the patient's immune response both at the time or original therapy and/or for later therapy.

Methods for treating cancer

A method for treating cancer comprising the steps of genetically sequencing a patient healthy tissue, genetically sequencing a patient tumor tissue, comparing the genetic sequences of the healthy tissue and tumor tissue to identify one or more mutations specific to the tumor tissue, generating a library of 9-mers having one or more peptide fragments specific to the tumor tissue, and identifying a 9-mer that elicits the strongest immune response in the patient.. .

Recombinant aav vectors useful for reducing immunity against transgene products

The disclosure in some aspects, relates to nucleic acids, compositions and kits useful for gene therapy with reduced immune response to transgene products.. .
University Of Massachusetts

Lentiviral vectors for regulated expression of a chimeric antigen receptor molecule

The invention relates to the regulated expression of a chimeric antigen receptor (car) within a lentiviral vector. The car comprises a hook-binding domain that interacts with a hook, preferably encoded by the same lentiviral vector, which prevents proper processing and release of the car to the cell membrane.
Institut National De La Sante Et De La Research Medical (inserm)

Immunostimulatory combinations of tlr ligands and methods of use

The present invention provides immunostimulatory combinations of tlr ligands and therapeutic and/or prophylactic methods that include administering an immunostimulatory combination to a subject. In general, the immunostimulatory combinations described herein can provide an increased immune response compared to other immunostimulatory combinations and/or compositions..
The United States Of America, As Represented By The Secretary, Department Of Health & Human Servic

Immunotherapy composition and use thereof

The present invention relates to the field of preventing or reducing incidence or severity of an allergic immune response, and compositions for preventing or reducing incidence or severity of an allergic immune response. For example, the present invention provides compositions comprising inactivated and/or killed cells of helicobacter pylori or a cell lysate thereof, and methods and/or uses thereof for delaying or preventing or interrupting or slowing onset of one or more allergic conditions in a subject..
Ondek Pty Ltd

Novel vaccines against multiple subtypes of influenza virus

An aspect of the present invention is directed towards dna plasmid vaccines capable of generating in a mammal an immune response against a plurality of influenza virus subtypes, comprising a dna plasmid and a pharmaceutically acceptable excipient. The dna plasmid is capable of expressing a consensus influenza antigen in a cell of the mammal in a quantity effective to elicit an immune response in the mammal, wherein the consensus influenza antigen comprises consensus hemagglutinin (ha), neuraminidase (na), matrix protein, nucleoprotein, m2 ectodomain-nucleo-protein (m2e-np), or a combination thereof.
The Trustees Of The University Of Pennsylvania

Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same

Nucleic acid molecules and compositions comprising one or more nucleic acid sequences that encode a consensus filovirus immunogen including a consensus marburgvirus filovirus glycoprotein marv gp immunogen, a consensus ebolavirus sudan filovirus glycoprotein sebov gp immunogen and a consensus ebolavirus zaire glycoprotein zebov gp immunogen are disclosed. The coding sequences optionally include operable linked coding sequence that encode a signal peptide.
The Trustees Of The University Of Pennsylvania

Aipa, ompa, and asp14 in vaccine compositions and diagnostic targets for anaplasma phagocytophilum infection

Anaplasma phagocytophilum surface protein aipa and/or fragments thereof which comprise an invasin domain are used in compositions suitable to elicit an immune response to treat or prevent infections caused by tick-born bacteria of the anaplasmatacaea family. Aipa proteins and protein fragments or antibodies directed to aipa proteins and protein fragments are also used in diagnostic assays to detect exposure to and/or infection with anaplasmatacaea.
Virginia Commonwealth University

Replication defective adenovirus vector in vaccination

Methods for generating immune responses using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to adenovirus are provided.. .
Etubics Corporation

Novel peptides and combination of peptides for use in immunotherapy against cll and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against cll and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Methods and compositions for transgene expression in a herpesvirus vector system

Compositions are provided comprising a replication-competent herpesvirus vector system and/or a herpesvirus vector particle comprising a heterologous recombinant transgene of interest encoding an antigen of interest (e.g., a tumor-associated antigen, a microbial antigen, etc.), wherein the recombinant transgene has been modified to comprise a codon usage signature of a herpesvirus late gene operably linked to an active promoter. Such compositions find use in a variety of methods including, for example, methods of generating an immune response against an antigen of interest in a subject in need thereof, as well as methods for treating or preventing cancer or a microbial infection..
President And Fellows Of Harvard College

Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Compositions and methods for modulation of rorgammat functions

The present invention relates to expression of rorγt in cells and tissues and the effect of expression of this gene on proliferation of specific immune cells and in promotion of immune cell aggregates and in induction of il17 producing cells. Furthermore, the invention relates to methods and agents that may decrease function of the gene product (the protein) or expression of this gene in individuals experiencing an inflammatory condition, an autoimmune disease or a food allergy, or any other condition whereby it is desirable to inhibit an immune response.

Anti-laminin4 antibodies specific for lg1-3

The invention provides antibodies that specifically bind to the lg1-3 modules of the g domain of laminin α4. The antibodies have the capacity to inhibit binding of laminin α4 to mcam.
Prothena Biosciences Limited

Novel peptides and combination of peptides for use in immunotherapy against various tumors

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Sulfated-glycolipids as adjuvants for vaccines

A synthetic charged glycolipid is described comprising a sulfated saccharide group covalently linked to the tree sn-1 hydroxyl group of the glycerol backbone of an archaeal core lipid via a beta linkage. The synthetic charged glycolipids include compounds of formula i wherein n is 0 or 1; r is hydrogen or hydroxyl; and y is hydrogen or a sulfate group, at least one y being a sulfate group; and including pharmaceutically acceptable salts thereof.
National Research Council Of Canada

Laser adjuvants for enhancing immune response

Methods for enhancing an immune response to a vaccine using co-administration of radiation.. .
The General Hospital Corporation

Methods and compositions for liposomal formulation of antigens and uses thereof

The present invention relates to liposomal vaccine compositions, methods for the manufacture thereof, and methods for the use thereof to stimulate an immune response in an animal. These compositions comprise dimyristoylphosphatidylcholine (“dmpc”); either dimyristoylphosphatidylglycerol (“dmpg”) or dimyristoyltrimethylammonium propane (“dmtap”) or both dmpc and dmtap; and at least one sterol derivative providing a covalent anchor for one or more immunogenic polypeptide(s) or carbohydrate(s)..
The Regents Of The University Of California

Manf as a regulator of immune system function

Methods and compositions for enhancing an immunological response by administering an immunogenic composition comprising an effective amount of a manf family protein or fragment thereof and an antigen to a subject. Also, methods and compositions for decreasing an immune response by inhibiting or antagonizing the activity of a manf family protein..
University Of Massachusetts

Compositions and methods of enhancing immunogenicity of polysaccharide protein conjugates

The present invention provides compositions and methods for enhancing immunogenicity of polysaccharide antigens. Immunogenic compositions and vaccines comprising polysaccharide-protein conjugates comprising a chimeric carrier protein having a universal epitope are provided.
Kanvax Biopharmaceuticals Ltd

Method for the production of recombinant virus, dna constructs, recombinant virus and vaccine compositions

The purpose of the present invention is the production of recombinant virus through the cloning and expression of sequences of coding nucleotides of the whole or part of heterolog proteins, through the following method: (a) modification of the heterolog nucleotides sequences in such way they when cloned and expressed in the vector virus, the present in the 5′ region nucleotides present in the 5′ edge of the gene ns1 of this vector virus or of other virus or equivalent functional sequences, and in its 3′ region, the correspondent genome region in the whole or part of the spheres of the steam and anchor of the protein e of this vector virus or equivalent functional sequences, and not comprising the structure and the replication of the mention vector virus; (b) insertion of the modified heterolog sequences in (a) in the intergene region at the structural protein e level and of constructural ns1 vector virus; (c) obtention of the non pathogenic recombinant virus and owner of the immunologic properties, having the heterolog sequences integrated in the viral genome according to the insertion described in (b) and, like that, expressing the heterolog antigene in such way that it can induce an appropriate immune response. The present invention is also addressed to vaccine compositions to immune against the flavivirus and/or other patogens..

Therapeutic cancer vaccine

The present invention relates to vaccine(s) comprising cancer cells expressing antigen(s), excipients, optionally adjuvant wherein the said antigen(s) is expressed on contacting the said cancer cell with p38 inducer, for use in treatment of cancer. The vaccine composition induces specific immune response against homologous and heterologus cancer cells of the tissue/organ.
Cadila Pharmaceuticals Ltd.

Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates

Methods and compositions for preventing an immune response to an immunogenic therapeutic agent [i.e. Anti-drug antibody (ada), a.k.a.
Jomoco, Corp.

Smart car devices and de car polypeptides for treating disease and methods for enhancing immune responses

In an aspect, the present invention relates generally to the field of treating disease with car devices, smart car devices, de car devices, and/or smart-de car devices. The present invention also relates generally to the genetic modification of cytotoxic t-lymphocytes to reduce target cell killing by apoptosis and/or increase production of lytic proteins at desired times.
Chimera Bioengineering, Inc.

Drug regulated transgene expression

The present invention provides nucleic acids, vectors, host cells, methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring cd8+ central memory t cells or combinations of central memory t cells with cd4+ t cells that are genetically modified to express a chimeric receptor under the control of an inducible promoter. In some alternatives the genetically modified host cell comprises a nucleic acid comprising a polynucleotide coding for a chimeric antigen receptor comprising a ligand binding domain, a polynucleotide comprising a spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain under the control of a drug inducible promoter.
Seattle Children's Hospital (dba Seattle Children's Research Institute)

Induction of immunotolerance

The present invention provides for a novel method for inhibiting an undesirable immune response, especially in transplant recipients such as those having received an allogeneic stem cell transplant. Also disclosed are related compositions and kits for inducing immunotolerance..
The Chinese University Of Hong Kong

Recombinant swine influenza virus and uses thereof

Recombinant, chimeric porcine influenza viruses are disclosed that include hemagglutinin segments from more than one influenza virus subtype. Also described are methods of producing the recombinant influenza viruses, immunogenic compositions comprising the recombinant influenza viruses, methods of stimulating an immune response against influenza virus, and methods of treating and preventing influenza virus infection..
University Of Saskatchewan

Vaccines for human papilloma virus and methods for using the same

Improved anti-hpv immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus hpv39 e6e7 and hpv45 e6e7.
Inovio Pharmaceuticals, Inc.

Anti-mycoplasma spp. subunit vaccine

Provided in the present invention are anti-mycoplasma spp. Subunit vaccines, especially proteins suitable for being used as the active ingredient of the mycoplasma spp.
Agricultural Technology Research Institute

Enhanced immune response in cattle upon treatment with nitric oxide

The present invention relates to a method of immune activation which is effective for eliciting a non-antigen-specific immune response in a member of the bovine species. The method is particularly effective for protecting a member of the bovine species from infectious disease and treating animals inflicted with infectious disease..
Bovicor Pharmatech Inc.

Use of leukotriene b4 in combination with a toll-like receptor ligand, a rig-i-like receptor ligand, or a nod-like receptor ligand to enhance the innate immune response

The present invention relates to the use of leukotriene b4 to enhance the response of toll-like receptor (tlr), rig-i-like receptor (rlr), and nod-like receptor (nlr) when stimulated simultaneously with respective proper ligands. The use in combination of ltb4 with those ligands is useful to potentiate immune response for the treatment of autoimmune diseases, immunosuppressive diseases, as well as immunological disorders..
Universite De Laval

Compositions, kits and methods for in vitro antigen presentation, assessing vaccine efficacy, and assessing immunotoxicity of biologics and drugs

Nanoparticle-based compositions, assays, kits, methods and platforms for delivering an antigen (peptides, proteins) or a nucleic acid encoding an antigen to professional apcs (papcs) result in the generation of autologous apcs that present a natural peptide repertoire of the antigen for use in assessing the efficacy of a vaccine (e.g., a cytotoxic t lymphocyte (ctl) response to a particular antigen) or other therapy or intervention (cell-based therapy, adjuvant therapy, etc.). The compositions, kits, assays and methods also can be used for delivering a drug or biologic or portion thereof to apcs for assessing the immunogenicity of drugs and biologics.

Methods for the treatment of infections and tumors

Pd-1 antagonists are disclosed that can be used to reduce the expression or activity of pd-1 in a subject. An immune response specific to an infectious agent or to tumor cells can be enhanced using these pd-1 antagonists in conjunction with an antigen from the infectious agent or tumor.

Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response

The invention provides novel immune regulatory oligonucleotides (iro) as antagonist of tlrs and methods of use thereof. These iros have unique sequences that inhibit or suppress tlr-mediated signaling in response to a tlr ligand or tlr agonist.

Hbv polymerase mutants

The present invention relates to polymerase hbv mutant polypeptides comprising a mutated polymerase domain which is functionally disrupted for polymerase activity and fusion proteins comprising such polymerase mutant polypeptide. The present invention also relates to a nucleic acid molecule and an expression vector for expressing said polymerase mutant polypeptide as well as a composition which can be used for eliciting an immune response to hbv with the goal of providing a protective or therapeutic effect against hbv infection..

Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease

The invention provides unique therapeutic and diagnostic antibodies, as well as their fragments, portions, derivatives, and variants thereof, that bind regions of the tau protein that contribute to the initiation and propagation of pathological tau-tau interactions, as well as methods of making them. The invention also relates to methods of using those antibodies for diagnostics, prevention, and treatment of alzheimer's disease and related tauopathies.

Novel peptides and combination of peptides for use in immunotherapy against various tumors

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.

Novel peptides and combination of peptides for use in immunotherapy against various tumors

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.

Immobilized tumor necrosis factor-alpha muteins for enhancing immune response in mammals

An extracorporeal system for enhancing an immune response in a mammal to facilitate the elimination of a chronic pathology. The system includes an absorbent matrix capable of removing an immune system inhibitors such as soluble tnf receptor from the circulation of the mammal, thus, enabling a more vigorous immune response to the pathogenic agent.

Novel mucosal adjuvants and delivery systems

Adjuvants comprising chitosan cross-linked with an aldehyde or mannosylated chitosan are provided herein. Methods of making the adjuvants and methods of combining or linking the adjuvants with antigens are also provided.

Immunogenic combinations

Immunogenic combinations that include a) an immunogenic component containing a peptide or polypeptide antigen of a respiratory pathogen; and b) an immunogenic component containing a nucleic acid encoding an antigen of the same respiratory pathogen, wherein the immunogenic components are formulated for concurrent administration are provided, as well as methods for making and for administering such immunogenic combinations to elicit an immune response specific for the respiratory pathogen.. .

Dengue virus vaccine

Recombinant fusion proteins including a dengue virus eiii and an e2 subunit derived from a thermophilic bacterium are described. Also described are expression vectors including a polynucleotide that encodes the recombinant fusion protein and a promoter.

Immunotherapy using cell-targeting molecules comprising shiga toxin a subunit effectors and cd8+ t-cell epitopes

The present invention provides cell-targeting molecules which can deliver a cd8+ t-cell epitope cargo to the mhc class i presentation pathway of the cell. The cell-targeting molecules of the invention can be used to deliver virtually any cd8+ t-cell epitope from an extracellular space to the mhc class i pathway of a target cell, which may be a malignant cell and/or non-immune cell.

Immunogenic glycopeptides, composition comprising the glycopeptides and use thereof

Disclosed herein are an immunogenic glycopeptide for inducing immune response to treat cancer. Other aspects of the present disclosure are pharmaceutical composition comprising the immunogenic glycopeptide; and method for preventing and/or treating a cancer..

Cmv vectors comprising microrna recognition elements

Disclosed herein are recombinant cmv vectors comprising heterologous antigens and microrna recognition elements to silence expression of cmv genes in the presence of microrna derived from myeloid cells, an active ul128 protein and an active ul130 protein. Also disclosed are recombinant cmv vectors comprising heterologous antigens and microrna recognition elements to silence expression of cmv genes in the presence of microrna derived from myeloid cells, an inactive ul128 protein and an inactive ul130 protein.

Use of cinnabarinic acid as a modulator of immune response in autoimmune disorders

The present invention provides compounds and methods for preventing and treating an immune disorder in a subject.. .

Adenosine receptor agonists and antagonists to modulate t cell responses

Described are uses of a2a adenosine receptor antagonists and agonists to provide long term modulation of immune responses. A2a receptor antagonists in particular are provided to enhance immune responses by reducing t-cell mediated tolerance to antigenic stimuli and agonists are provided to enhance effectiveness of immunosuppressive agents.

Recombinant poxviral vectors expressing both rabies and ox40 proteins, and vaccines made therefrom

The present invention provides vectors that contain and co-express in vivo or in vitro immunogenic polypeptides or antigens together with an ox40l polypeptide, which functions as a genetic adjuvant. Together, the immunogenic polypeptide and the ox40l polypeptide elicit an immune response in animal or human, which is greater than the immune response elicited by the immunogenic polypeptide alone.
Merial, Inc.

Therapeutic antibodies

A pharmaceutical comprising a therapeutic protein that binds to a therapeutic target, the protein being modified with a compound that inhibits binding of the protein to the therapeutic target, the modified protein being effective for reducing an immune response against the protein and for producing a therapeutic effect by binding to the therapeutic target. The therapeutic protein may be an antibody that includes an antibody combining site that binds to the therapeutic target..

Gitr antibodies and methods of inducing or enhancing an immune response

The present invention provides binding molecules that specifically bind to gitr, e.g., human gitr (hgitr), on t cells and dendritic cells. Binding molecules of the invention are characterized by binding to hgitr with high affinity, in the presence of a stimulating agent, e.g., cd3, are agonistic, and abrogate the suppression of teff cells by treg cells.
Gitr, Inc.

Ctla4 binders

The present invention provides molecules, such as isvds and nanobodies, that bind to ctla4 or human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule.

Pd1/ctla4 binders

The present invention provides multispecific molecules, e.g., comprising more than one isvd or nanobody, that bind to pd1 and ctla4. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule.

Pd1 and/or lag3 binders

The present invention provides molecules, such as isvds and nanobodies, that bind to pd1 and lag3 and, optionally to human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule.

Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof

The present invention provides isolated monoclonal antibodies that specifically bind lag-3, and have optimized functional properties compared to previously described anti-lag-3 antibodies, such as antibody 25f7 (us 2011/0150892 a1). These properties include reduced deamidation sites, while still retaining high affinity binding to human lag-3, and physical (i.e., thermal and chemical) stability.
Bristol-myers Squibb Company

Tgf-ß1 specific antibodies and methods and uses thereof

Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 1 (tgf-β1) are provided, particularly recognizing human and mouse tgf-β1 and not recognizing or binding tgf-β2 or tgf-β3. Particular antibodies are provided which specifically recognize and neutralize tgf-β1.

Induction of immune response

Provided are methods and compositions that can he used to treat subjects having a viral infection by provoking an immune response using newly discovered antigens that are non-naturally occurring variations on viral glycoproteins. For example, provided are viral glycoproteins or a fragments thereof, or, dna constructs encoding for such viral glycoproteins or fragments thereof, wherein the glycoprotein or fragment comprises a glycosylation sequon that includes a non-templated aspartic acid residue..
Drexel University

Pharmaceutical compositions comprising cpg oligonucleotides

The present invention provides a pharmaceutical composition for inducing immune response in a subject, comprising: (a) an antigen with a concentration ranging from 1 μg/ml to 100 μg/ml; (b) cpg oligonucleotides having a sequence of 5′-tcgacgttcgtcgttcgtcgttc-3′, with a concentration ranging from 25 μg/ml to 500 μg/ml, and (c) an aluminium adjuvant with a concentration ranging from 25 μg/ml to 500 μg/ml. Such pharmaceutical composition can induce or boost immune response against antigen in the subject..
Changchun Huapu Biotechnology Co., Ltd.

Vaccines comprising heat-sensitive transgenes

The present disclosure provides temperature sensitive essential nucleic acid molecules from a psychrophilic bacterium, proteins encoded by the nucleic acid molecules, as well as recombinant cells into which have been introduced such nucleic acid molecules. The disclosed recombinant cells containing one or more essential nucleic acid molecules from a psychrophilic bacterium are thereby made temperature sensitive, and can be administered to a mammal to induce an immune response in the mammal..
Uvic Industry Partnerships Inc.

Novel methods for inducing an immune response

Methods and uses are provided for inducing an immune response comprising at least two administrations of an immunogenic composition, wherein a lower dose is given in the second administration than in the first administration, and wherein the second administration may be unadjuvanted.. .
Glaxosmithkline Biologicals Sa

Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Methods and compositions for diagnosing, monitoring and treating cancer

The invention relates to methods for diagnosing cancer and determining the responsiveness to chemotherapyin a subject based on the detection of hsp70-expressing exosomes in a bodily fluid sample obtained from said subject. The invention also relates to methods for treating cancer and in particular methods for restoring or enhancing the anti-tumor immune response in a patient in need thereof by inhibiting the activation mdsc as well as methods for inhibiting or reducing hsp70-expressing exosomes-mediated tumor resistance against a chemotherapeutic agent and therefore methods for restoring or enhancing the efficacy of said chemotherapeutic agent..
Universite De Bourgogne

Humanized viral vectors and methods of use thereof

The present invention provides humanized viral vectors and methods of use thereof for delivery of transgenes or therapeutic nucleic acids to human subjects. Humanized viral vectors are modified from known viral vectors such as those based on aav by coating their surface with a human protein such as human serum albumin and optionally a lipid coating or formulation, so that the foreign or non-human nature of the vector is masked.
The Children's Hospital Of Philadelphia

Calcium flux agonists and methods therefor

Calcium flux agonists are used to enhance a tlr- or nod-mediated stimulus and to so increase an immune response of a host and reduce healing time. Preferred calcium flux agonists include ca2+ ionophores and serca inhibitors and are used in synergistic quantities where a ligand to a tlr or nod receptor is present..
Nant Holdings Ip, Llc

Polyvalent influenza virus-like particles (vlps) and use as vaccines

This disclosure provides compositions that include a mixture of viral like particles (vlps), expressing different individual influenza hemagglutinin (ha) proteins that elicit broadly reactive immune responses to a wide variety of influenza viruses. For example, the composition can include at least two different influenza vlps, a first vlp comprising a first ha polypeptide and a second vlp comprising a second influenza ha polypeptide, wherein the first and the second ha polypeptide are different subtypes and/or are from different influenza viruses, and a pharmaceutically acceptable carrier and/or an adjuvant.
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv

Use of oil and water emulsions for increasing b cell responses with modified vaccinia ankara virus

The invention relates to compositions, uses, and methods for inducing an immune response against a vaccinia virus. The addition of an oil and water emulsion to mva can vastly increase the b cell response and particularly neutralizing antibodies against vaccinia virus and encoded recombinant antigens.
Bavarian Nordic A/s

Attenuated mannheimia haemolytica vaccines and methods of making and use

The present invention provides attenuated m. Haemolytica strains that elicit an immune response in animals against m.
The United States Of America As Represented By The Secretary Of Agriculture

Capsular gram-positive bacteria bioconjugate vaccines

The present invention encompasses a novel s. Aureus bioconjugate vaccine.
Glycovaxyn Ag

Anti-malaria compositions and methods

Described herein are multilayer films that include modified polypeptide epitopes from plasmodium falciparum, specifically a modified t* epitope. The multilayer films are capable of eliciting an immune response in a host upon administration to the host.
Artificial Cell Technologies, Inc.

Complexes of rna and cationic peptides for transfection and for immunostimulation

The present invention relates to a complexed rna, comprising at least one rna complexed with one or more oligopeptides, wherein the oligopeptide, which has the function of cell-penetrating peptide (cpp), has a length of 8 to 15 amino acids and has the empirical formula (arg)l;(lys)m;(his)n;(om)o;(xaa)x with the majority of residues being selected from arg, lys, his, om. The invention further relates to a method for transfecting a cell or an organism, thereby applying the inventive complexed rna.
Curevac Ag

Recombinant viral vectors and methods for inducing a heterosubtypic immune response to influenza a viruses

The present invention relates to recombinant viral vectors and methods of using the recombinant viral vectors to induce an immune response to influenza a viruses. The invention provides recombinant viral vectors based, for example, on the non-replicating modified vaccinia virus ankara.
Nanotherapeutics, Inc.

Blockade of rgmb for reducing transplantation-associated immune responses

Rgmb antagonists reduce undesirable immune responses associated with tissue or organ transplantation.. .
The Board Of Trustees Of The Leland Stanford Junior University

Using b-cell-targeting antigen igg fusion as tolerogenic protein therapy for treating adverse immune responses

The present invention generally relates to antigen-specific tolerogenic protein therapy and the use thereof for treating adverse immune responses, including those associated with autoimmune diseases such as multiple sclerosis (ms) and hemophilia. In particular, the invention involves the application of a b cell-targeting igg fusion protein as the antigen-specific tolerogenic protein therapy, either alone or in combination with inhibitory antibodies.
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.

Computationally optimized broadly reactive antigens for h1n1 influenza

Described herein is the generation of optimized h1n1 influenza ha polypeptides for eliciting a broadly reactive immune response to h1n1 influenza virus isolates. The optimized ha polypeptides were developed through a series of ha protein alignments, and subsequent generation of consensus sequences, based on selected h1n1 viruses isolated from 1918-2011.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education

Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response

The present invention relates to the use of a recombinant lag-3 or derivatives thereof in order to boost a monocyte-mediated immune response, in particular to elicit an increase in the number of monocytes in blood. This finds use in the development of novel therapeutic agents for the treatment of an infectious disease or cancer..
Immutep

Dengue virus specific multiple hla binding t cell epitopes for the use of universal vaccine development

Dengue fever (df) and dengue hemorrhagic fever (dhf) are significant global public health problems and understanding the overall immune response to infection will contribute to appropriate management of the disease and its potentially severe complications. Live attenuated and subunit vaccine candidates, which are under clinical evaluation, induce primarily an antibody response to the virus and minimal cross-reactive t cell responses.
Immunotope, Inc.

Fusion molecule based on novel taa variant

This invention provides novel carbonic anhydrase (caix) nucleic acid and peptide sequences, as well as related methods and compositions, including anti-cancer immunogenic agent(s) (e.g. Vaccines and chimeric molecules) that elicit an immune response specifically directed against cancer cells expressing a caix antigenic marker.
The Regents Of The University Of California

Methods and compositions for modulating immune tolerance

The instant invention provides methods and compositions for modulation of the immune system. Specifically, the present disclosure provides methods and compositions for increasing t cell mediated immune response useful in the treatment of cancer and chronic infection..
The United States Of America, As Represented By The Secretary, Department Of Health & Human Servic

Useful process for screening immune response modifier

Immunovir and components were isolated from pyrus serotina rehder and other species of rosaceae by column chromatography.. .

Expression of mirnas in placental tissue

Provided are human mirnas associated with the generation of immunological tolerance during pregnancy as well as fragments, derivatives and variants thereof for use in immunomodulation. Said mirnas may be used in diagnosis and treatment of disorders associated with a deregulated immune response, autoimmune disorders, pregnancy associated diseases, failure or problems of placentation and complications resulting from allotransplantations.

Chimeric west nile/dengue viruses and methods of use

Disclosed herein are chimeric flaviviruses including non-coding regions, non-structural proteins, and at least a portion of a c protein from west nile virus (wnv), and a prm protein and an e protein from dengue virus (denv). The denv may be den1 serotype, den2 serotype, den3 serotype, or den4 serotype.
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services

Computationally optimized broadly reactive antigens for h1n1 influenza

Described herein is the generation of optimized h1n1 influenza ha polypeptides for eliciting a broadly reactive immune response to h1n1 influenza virus isolates. The optimized ha polypeptides were developed through a series of ha protein alignments, and subsequent generation of consensus sequences, based on selected h1n1 viruses isolated from 1918-2012.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education

Vesicular stomatitis virus for prime boost vaccine

The present invention relates to vesicular stomatitis virus (vsv) matrix (m) protein mutants. One mutant m protein includes a glycine changed to a glutamic acid at position 21, a leucine changed to a phenylalanine at position 111 and a methionine changed to an arginine at position 51.
The University Of Western Ontario

Novel compound having immune disease treatment effect and use thereof

The present invention relates to a novel compound capable of effectively preventing and treating immune diseases and a use thereof. The novel compound of the present invention has effects of inhibiting the production of inflammatory cytokines, increasing the activity of regulatory t cells having immunoregulatory functions, inhibiting the production of auto-antibodies to regulate excessive immune responses, and inhibiting the differentiation of osteoclasts, and thus can be used for treating immune diseases, such as autoimmune disease, inflammatory disease, and transplant rejection diseases, which are caused by abnormal regulation of various kinds of immune response.
The Catholic University Of Korea Industry-academic Cooperation Foundation

Vista modulators for diagnosis and treatment of cancer

The present disclosure relates to compositions and therapeutic methods for activating an immune response in a patient in need thereof. In a preferred embodiment, the subject methods and compositions are able to antagonize the activity of vista, a naturally occurring “checkpoint” protein which contributes to immune tolerance, optionally in combination with an antagonist of a second checkpoint pathway such as pd-1.
The Trustees Of Dartmouth College

Vesicular stomatitis virus for prime boost vaccine

The present invention relates to vesicular stomatitis virus (vsv) matrix (m) protein mutants. One mutant m protein includes a glycine changed to a glutamic acid at position 21, a leucine changed to a phenylalanine at position 111 and a methionine changed to an arginine at position 51.
The University Of Western Ontario

Novel methods for inducing an immune response

Methods and uses are provided for inducing an immune response comprising at least two administrations of an immunogenic composition comprising an m72 related antigen and wherein a subsequent administration is delayed.. .
Glaxosmithkline Biologicals S.a.

Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors

The present disclosure relates to methods of treating, ameliorating or preventing a disorder comprising administering a therapeutically effective amount of a composition comprising a protein which inhibits the ligand of uniprot #p05112 and/or the ligand of uniprot #p35225 from binding to their respective receptors to a subject in need thereof. In some embodiments, the disorder is preferably associated with an increase of the th2 immune response.
Pieris Pharmaceuticals Gmbh

Methods of using anti-pd-l1 antibodies and their use to enhance t-cell function to treat tumor immunity

The present application relates to anti-pd-l1 antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use enhance t-cell function to upregulate cell-mediated immune responses and for the treatment of t cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.. .
Genentech, Inc.

Computationally optimized broadly reactive antigens for human and avian h5n1 influenza

Described herein is the generation of optimized h5n1 influenza ha polypeptides for eliciting a broadly reactive immune response to h5n1 influenza virus isolates. The optimized ha polypeptides were developed through a series of ha protein alignments, and subsequent generation of consensus sequences, based on human and avian h5n1 isolates.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education

Cytokine-chitosan bioconjugates and methods of using the same

Compositions including chitosan covalently linked to a cytokine or growth factor are provided herein. The compositions can be used to produce pharmaceutical compositions and can be used in methods of treating a variety of diseases or disorders.
The Board Of Trustees Of The University Of Arkansas

Cellular vaccine and inducing an immune response in a subject

The present invention relates to methods of inducing or enhancing an immune response against an immunogen in a subject. The invention further includes isolated nucleic acid vaccines, cellular vaccines, fusion proteins, expression vectors, vaccines, and immunogenic compositions for use therein..
Adelaide Research & Innovation Pty Ltd.

Influenza virus vectors and uses therefor

Disclosed herein are compositions and methods related to mutant viruses, and in particular, mutant influenza viruses. The mutant viruses disclosed herein include a mutant m2 sequence, and are useful in immunogenic compositions, e.g., as vaccines.
Flugen, Inc.

Haemophilus influenzae type iv pili

The invention described herein relates to a haemophilus influenzae (h. Influenzae) regulon encoding type iv pili.
Nationwide Children's Hospital, Inc.

Influenza vaccine, composition, and methods of use

The invention relates to compositions and vaccines that include a mutated bordetella strain for treating or preventing an influenza infection in a mammal. In addition, the invention further provides methods for protecting a mammal against infection by influenza and/or eliciting an immune response against an influenza virus in a mammal using the composition or vaccine..
National University Of Singapore

Recombinant mycobacterium bovis bcg expressing antigens of the mycobacterium marinum esx-1 secretion system

Recombinant strains of mycobacterium bovis bacille calmette-guerin (m. Bovis bcg) comprising a heterologous nucleic acid sequence of mycobacterium marinum (m.
Institut Pasteur

Multi-component-multistage malaria vaccines

The present disclosure relates to novel malaria vaccines composed of different recombinant proteins, in particular recombinant fusion proteins comprising several different plasmodium falciparum antigens from the pre-erythrocytic the blood, and the sexual parasite stages. The proteins and/or fusion proteins will be used in a mixture vaccine formulation to elicit protective immune responses in humans.
Fraunhofer-gesellschaft Zur Foerderung Der Angewandten Forschung E.v.

Methods and compositions for treating autoimmune and inflammatory conditions

Described herein are compositions and methods for inhibiting an inflammatory or autoimmune response and for inducing immune tolerance in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an antigen presenting cell (apc)-targeted antibody operatively linked to il-10 or a fragment thereof. The compositions and methods described herein are useful for treating inflammatory and autoimmune disorders..
Baylor Research Institute

Flavonoid compositions and methods of use

Flavonoid compositions containing the flavonoid quercetin and/or derivatives of quercetin are disclosed. The flavonoid compositions are formulated to improve the bioavailability of quercetin.
Reoxcyn Discoveries Group, Inc.

Modulated immunodominance therapy

The invention involves generating a t cell response to subdominant antigens and using the cells to therapeutically change the cellular homeostasis and nature of the immune response. In a preferred embodiment, the cells are generated outside of the patient avoiding the influence of the patient's immunologic milieu.
Geneius Biotechnology, Inc.

Method for decreasing immunogenicity of protein and peptide

The present invention relates to a method for increasing serum half-life of a protein or peptide and decreasing immunogenicity thereof by site-specifically binding a carrier to a protein or peptide, and to the use thereof. The conjugate of the physiologically active protein or peptide of the present invention can significantly decrease immunogenicity in the human body and thus reduce antibody production rate against the protein or peptide.
Hanmi Pharm. Co., Ltd.

Activation of immune-related signaling pathways in cells via optofection

Systems and methods of inducing large-scale optical transfection and generation of an immune response in target cells are presented. In preferred aspects large-scale optofection uses nanoparticles with target specific affinity moieties to generate cavitation events proximal to the cell membrane of cells to which the nanoparticles are attached, and suspended and/or dissolved cargo is so provided access into the cell.
Nant Holdings Ip, Llc

Induction of mucosal tolerance to antigens

The present invention relates to the induction of tolerance to antigens, by mucosal, preferably oral delivery of the antigen in combination with an immunomodulating compound producing micro-organism. More specifically, the invention relates to the induction of foxp3+ and/or il-10 and/or tgf-β producing regulatory t-cells, capable of suppressing undesired immune responses toward an antigen, by oral delivery of said antigen in combination with an immunosuppressing cytokine secreting micro-organism..
Intrexon Actobiotics Nv

Combination vaccines with serogroup b meningococcus and d/t/p

Serogroup b meningococcus antigens can successfully be combined with diphtheria, tetanus and pertussis toxoids (“dtp”) to provide effective combination vaccines for protecting against multiple pathogens. These combinations are effective with a range of different adjuvants, and with both pediatric-type and booster-type dtp ratios.
Glaxosmithkline Biologicals Sa

Amplification of epitope specific personalized anti-angiogenic immune responses

Disclosed are therapeutic means, protocols, and compositions of matter useful for treatment of cancer by eliciting and amplifying immune responses specific to antigens found on tumor endothelium. In one embodiment of the invention a patient is immunized with a polyvalent anti-angiogenic vaccine, subsequent to which assessment is made in a patient specific manner of the immune targets that are recognized in response to the immunizing mixture.
Batu Biologics, Inc.

Strategies to prevent and/or treat immune responses to soluble allofactors

The present invention relates to the use of immunogenic peptides comprising a t-cell epitope derived from a soluble allofactor and a redox motif such as c-(x)2-[cst] or [cst]-(x)2-c in the prevention and/or suppression of immune responses to said soluble allofactor and in the manufacture of medicaments therefore.. .
Life Sciences Research Partners Vzw

Methods and compositions for immunomodulation

The methods and uses described herein relate to the modulation of the immune system by modulation of sema3f levels and/or activity, e.g. Suppressing allograft rejection or inflammation by administering a sema3f agonist or increasing an immune response by administering a sema3f inhibitor..
Children's Medical Center Corporation

Treatment of glioma by anti-angiogenic active immunization for direct tumor inhibition and augmentation of chemotherapy, immunotherapy and radiotherapy efficacy

Disclosed are compositions of matter, therapeutic protocols, and immunization means to induce an active immune response to vasculature feeding glioma or other brain neoplasia. In one embodiment the invention provides administration of placental derived endothelial cells at concentrations of 10 million to 50 million administered in a manner to stimulate immunity toward blood vessels supplying glioma or other brain neoplastic malignancies.
Batu Biologics, Inc.

Mature dendritic cell compositions and methods for culturing same

This invention provides methods to prepare and use immunostimulatory cells for enhancing an immune response. The invention provides a method for preparing mature dendritic cells (dcs), comprising the sequential steps of: (a) signaling isolated immature dendritic cells (idcs) with a first signal comprising an interferon gamma receptor (ifn-γr) agonist and/or a tumor necrosis factor alpha receptor (tnf-αr) agonist to produce signaled dendritic cells; and (b) signaling said signaled dendritic cells with a second transient signal comprising an effective amount of a cd40 agonist to produce ccr7+ mature dendritic cells.
Argos Therapeutics, Inc.

Mature dendritic cell compositions and methods for culturing same

This invention provides methods to prepare and use immunostimulatory cells for enhancing an immune response. The invention provides a method for preparing mature dendritic cells (dcs), comprising the sequential steps of: (a) signaling isolated immature dendritic cells (idcs) with a first signal comprising an interferon gamma receptor (ifn-γr) agonist and/or a tumor necrosis factor alpha receptor (tnf-αr) agonist to produce signaled dendritic cells; and (b) signaling said signaled dendritic cells with a second transient signal comprising an effective amount of a cd40 agonist to produce ccr7+ mature dendritic cells.
Argos Therapeutics, Inc.

Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Cyaa-based chimeric proteins comprising a heterologous polypeptide and their uses in the induction of immune responses

The invention relates to a chimeric protein comprising or consisting of, from n-terminal to c-terminal, (a) a n-terminal part of a bordetella cyaa protein (b) a heterologous polypeptide, and (c) a c-terminal part of a bordetella cyaa protein. The invention also relates to a polynucleotide encoding a deleted version of a bordetella cyaa, as well as a polynucleotide encoding this chimeric protein.
Genticel

Inhibition of gliadin peptides

Novel compounds and methods for the inhibition of biological barrier permeability and for the inhibition of peptide translocation across biological barriers are identified. Assays for determining modulators of biological barrier permeability and for peptide translocation across biological barriers are provided.
Alba Therapeutics Corporation

Amino acid and peptide conjugates and conjugation process

The present invention relates to amino acid and peptide conjugates, methods for making amino acid and peptide conjugates, conjugates produced by the methods, pharmaceutical compositions comprising the conjugates, methods of eliciting immune responses in a subject and methods of vaccinating a subject, uses of the conjugates for the same, and uses of the conjugates in the manufacture of medicaments for the same.. .
Auckland Uniservices Limited

Inhibition of tumor angiogenesis by checkpoint inhibitors and active vaccination

Disclosed are compositions of matter, methods, and protocols useful for treatment of cancer through induction of anti-angiogenic immune responses by vaccination together with immune modulation triggered by checkpoint inhibitors. The invention provides placenta, placental endothelial, placental fibroblasts, and mixtures thereof as immunogens, whose anti-angiogenic activity is augmented by utilization of checkpoint inhibitors.
Batu Biologics, Inc.

Lectin compositions and methods for modulating an immune response to an antigen

The present invention provides a fusion polypeptide which can bind to a cell surface binding moiety (e.g., a carbohydrate) and serve as a ligand for a cell surface polypeptide, as well as a vector comprising a nucleic acid encoding for such a fusion polypeptide, and a host cell comprising such nucleic acid. The present invention also provides a composition comprising an antigen bearing target and such a fusion polypeptide, as well as a composition comprising a virus or a cell and such a fusion polypeptide.
Opsanitx Llc

Methods and compositions for eliciting an immune response against hepatitis b virus

The present invention relates to immunization of hypo-responsive groups of individuals. In particular, the present invention provides methods and compositions for eliciting a potent immune response to hepatitis b virus in individuals in need thereof..
Dynavax Technologies Corporation

Hendra virus recombinant compositions and uses thereof

The present invention provides vectors that contain and express in vivo or in vitro one or more hendra virus polypeptides or antigens that elicit an immune response in animal or human against hendra virus and nipah virus, compositions comprising said vectors and/or hendra virus polypeptides, methods of vaccination against hendra virus and nipah virus, and kits for use with such methods and compositions.. .
Merial, Inc.

Medicament for use in a inducing or extending a cellular cytotoxic immune response

The present invention relates to a medicament for use in a method of extending a cellular cytotoxic immune response against an antigen-comprising protein, the method comprising the step of: i) administering to a patient having t cells activated against an antigen a peptide-loaded major histocompatibility complex class i (mhc-i) presenting cell and an adjuvant which supports a th-1-mediated response, wherein the peptide is derived from the antigen-comprising protein, thereby re-activating the activated t cell, wherein the peptide-loaded major histocompatibility complex class i (mhc-i) presenting cell of step i) is administered in a time frame of from 0 h to 14 days after the t cells were activated against an antigen.. .
Bundesrepublik Deutschland Ietzvertreten Durch Das Robert Koch-institut Vertreten Durch Seinen Präsi

Genetic engineering of macrophages for immunotherapy

Disclosed are methods of making a genetically modified immune cell for modifying a tumor microenvironment (tme) and methods of modifying a tumor microenvironment (tme). In some embodiments, the method can include delivering a first vector to an immune cell, wherein the first vector comprises a nucleic acid encoding a protein that induces t-cell proliferation, promotes persistence and activation of endogenous or adoptively transferred nk or t cells and/or induces production of an interleukin, an interferon, a pd-1 checkpoint binding protein, hmgb1, myd88, a cytokine or a chemokine.
Seattle Children's Hospital (dba Seattle Children' S Research Institute)

Recombinant poxvirus vector comprising tetanus toxin fragment c

The present invention relates to a recombinant poxvirus comprising tetanus toxin fragment c for improved immunogenicity of an antigen and related methods and uses. Specifically, the present invention generally relates to genetically engineered (recombinant) poxvirus vectors comprising a tetanus toxin fragment c (ttc) coding sequence operably linked to a bacterial antigenic determinant as well as to uses thereof, e.g., to affect an immune response in a subject..
Bavarian Nordic A/s

Immunomodulating beta-1,6-d-glucans

This invention relates to modifications of β-1,6-d-glucans, e.g., structures according to formula (i), and the ability of these compositions to modulate an immune response.. .
Immunexcite, Inc.

Regulatable chimeric antigen receptor

Provided are compositions and methods relating to regulatable chimeric antigen receptors (rcars), natural killer cell receptor cars (nkr-cars), and regulatable nkr-cars (rnkr-cars), where the intracellular signaling or proliferation of the rcar or rnkr-car can be controlled to optimize the use of an rcar/nkr-car- or rnkr-car-expressing cell to provide an immune response. Cells can be engineered to express a rnkr-car or to express a rcar and a nkr-car (e.g., inhibitory nkr-car).
The Trustees Of The University Of Pennsylvania

Mesothelin-targeted chimeric antigen receptors and uses thereof

The presently disclosed subject matter provides for methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to chimeric antigen receptors (cars) that specifically target human mesothelin, and immunoresponsive cells comprising such cars.
The U.s.a. As Represented By The Secretary, Department Of Health And Human Services

Peptide antagonist of ll-37

This disclosure is related to the peptide antagonist of ll-37, an antimicrobial peptide that has multiple functions in both innate and adaptive immune response. Specifically, the identified peptide antagonists of ll-37 provide inhibition to detrimental autoimmune inflammatory response, whereas at the same time retain ll-37's antibacterial activity..
Janssen Biotech, Inc.

Composition and diagnosis and immunotherapy of lung cancer

The present invention includes compositions and methods for the diagnosis and treatment of lung cancer with a recombinant tumor-associated antigen loaded antigen presenting cell that generates a cytotoxic t lymphocyte specific immune response to at least one of sp17, akap-4, or pttg1 expressed by one or more lung cancer cells.. .
Texas Tech University System

Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Modified adenoviruses for cancer vaccines development

The present invention relates to adenoviral vectors, wherein the viral capsid has been coated with polypeptides, which are capable of stimulating a peptide-specific immune response in a subject and uses thereof. Furthermore, the present invention relates to methods of treating diseases, e.g.
Helsingin Yliopisto

A medicament for use in a inducing or extending a cellular cytotoxic immune response

The present invention relates to a medicament for use in a method of inducing a cellular cytotoxic immune response, the method comprising the steps of: i) administering to a patient a delivery system comprising (a) a molecule binding to a receptor on the surface of a dendritic cell, (b) an antigen-comprising protein bound to molecule of (a) and (c) a first adjuvant, wherein upon binding of the molecule of (a) to the receptor, the protein of (b) is internalized and processed in the dendritic cell and the antigen comprised in the protein is presented on the surface of the dendritic cell, thereby activating a t cell in the patient; and ii) administering to the patient a re-activator selected from the group consisting of (d) complexed interleukin 2 (il-2cx), (e) a peptide-loaded major histocompatibility complex class i (mhc-i) presenting cell and a second adjuvant, and (f) a combination of (d) and (e), wherein the peptide is derived from the antigen-comprising protein as defined in step i), thereby reactivating the t cell activated in step i), wherein the re-activator of step ii) is administered in a time frame of from 0 h to 14 days after the administration of the delivery system of step i).. .
Bundesrepublik Deutschland Ietztvertreten Durch Da S Robert Koch-institut Vertreten Durch Seinen Prä

Methods and compositions for increasing a t-effector cell to regulatory t cell ratio

The present invention is directed to methods for increasing t-cell effector cell to regulatory t cell ratio. The invention is further directed to methods of treating, protecting against, and inducing an immune response against a tumor, comprising the step of administering to a subject a recombinant listeria strain, comprising a fusion peptide that comprises an llo fragment and tumor-associated antigen..
National Institutes Of Health (nih), U.s. Dept. Of Health And Humans Services (dhhs), U.s. Governmen

Flavonoid compositions and methods of use

Flavonoid compositions containing the flavonoid quercetin and/or derivatives of quercetin are disclosed. The flavonoid compositions are formulated to improve the bioavailability of quercetin.
Reoxcyn Discoveries Group, Inc.

Humanized monoclonal antibodies and methodsof use

The present invention comprises a humanized monoclonal antibody that binds to the human immunoglobulin heavy chain variable region germline gene vh1-69. This antibody is derived from mab g6 and recognizes the same epitope.
Dana-farber Cancer Institute, Inc.

Monoclonal antibodies to interleukin 35 and methods of use thereof to inhibit regulatory t cell function

Methods for regulating t cell function in a subject, particularly regulatory t cell activity are provided. Methods of the invention include administering to a subject a therapeutically effective amount of an interleukin 35-specific binding agent, such as an antibody or small molecule inhibitor.
St. Jude Children's Research Hospital

Compositions and methods for anti-lyst immunomodulation

Excessive or repeated activation of inflammatory and pro-coagulant mechanisms at the site of tissue injury contributes to the development scar tissue that can lead to intimal hyperplasia and fibrotic disease. It has been established that inhibition of the lyst protein is associated with reduced inflammatory responses and reduced platelet activation at the site of tissue damage.
Research Institute At Nationwide Children's Hospital

Particulate vaccine formulations for inducing innate and adaptive immunity

Disclosed are compositions, kits, and methods for inducing an immune response against an infection or a disease. The compositions typically include biodegradable particles having an average effective diameter that such that the biodegradable particles are phagocytosed by antigen presenting cells when the biodegradable particles are administered to a subject in need thereof.
Auburn University

A composition comprising ex-vivo generated dendritic cells

The present invention relates to a composition comprising ex-vivo generated antigen-loaded dendritic cells in combination with β-glucan and hyaluronic acid or pharmaceutically acceptable derivatives thereof and methods of preparing and delivering the same. The present composition of the present invention enhances antigen-specific t cell response against cancer cells.

Novel immunogenic composition

Recombinant chimeric viruses based on ndv lasota strain and containing either iltv gb or gd are produced. Administration of the chimeric viruses to chickens induces an immune response in the animal against both ndv and iltv.
The United States Of America, As Represented By The Secretary Of Agriculture

Multivalent vlp conjugates

The invention is directed to vaccines comprising capsular polysaccharides conjugated to one or more components of virus like particles (vlp), and methods for the administration of and methods for the manufacture of vaccines of the invention. Preferably vaccines of the invention generate a therapeutically effective response in an individual in need thereof to multiple strains and/or serotypes of the same or of different infectious agents.
Inventprise, Llc

Antigen specific multi epitope vaccines

The presently described subject matter relates to cancer vaccines composed of the signal peptide domain of tumor associated antigens or proteins. The described peptide vaccines have multiple mhc class i and class ii epitopes which are highly abundant in the population.
Vaxil Biotherapeutics Ltd.

Tumor vaccination involving a humoral immune response against self-proteins

The present invention relates to tumor immunotherapy, in particular to tumor vaccination, using chimeric proteins comprising all or a portion of a hepatitis b virus core antigen protein and an amino acid sequence comprising an epitope derived from the extracellular portion of a tumor-associated antigen. In particular, the present invention provides virus-like particles comprising said chimeric proteins, which are useful for eliciting a humoral immune response in a subject against the tumor-associated antigen, in particular against cells carrying said tumor-associated antigen on their surface, wherein the tumor-associated antigen is a self-protein in said subject..
Biontech Ag

Prenatal therapy to induce immune tolerance

Constructs and methods for inducing immune tolerance during gestation, e.g. In utero, are provided.
Inserm (institut National De La Santé Et De La Recherche Médicale)

Enhancing serological assays via fusion proteins

A serological assay with an improved linear range of detection is disclosed using a fusion protein system, such as an anti-cytokine/cytokine fusion protein (acyf) system, for evaluating immune responses. Also disclosed are related compositions, fusion proteins, expression vectors, monoclonal antibodies, and kits for practicing the assay method of the present invention..
Cornell University

Attenuated viruses useful for vaccines

This invention provides an attenuated virus which comprises a modified viral genome containing nucleotide substitutions engineered in multiple locations in the genome, wherein the substitutions introduce synonymous deoptimized codons into the genome. The instant attenuated virus may be used in a vaccine composition for inducing a protective immune response in a subject.
The Research Foundation For The State University Of New York

Method for in situ inhibition of regulatory t cells

The present invention pertains to engineered t-cells, method for their preparation and their use as medicament, particularly for immunotherapy. The engineered t-cells of the invention are designed to express both a chimeric antigen receptor (car) directed against at least one antigen expressed at the surface of a malignant or infected cell, and a secreted inhibitor of regulatory t-cells (treg).
Cellectis



Immune Response topics:
  • Immune Response
  • Antibodies
  • Polypeptide
  • Monoclonal
  • Monoclonal Antibody
  • Polymyxin B
  • Immunostimulator
  • Vaccination
  • Stimulator
  • Immunogenic
  • Nucleic Acid
  • Major Histocompatibility Complex
  • Histocompatibility
  • Vaccine Adjuvant
  • Compatibility


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Immune Response for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immune Response with additional patents listed. Browse our RSS directory or Search for other possible listings.


    5.0311

    file did exist - file did put13062

    5 - 1 - 253